bevacizumab + binimetinib + hydroxychloroquine

This is an investigational combination therapy consisting of three agents: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. - **Binimetinib** is a small molecule inhibitor targeting MEK1/2, key kinases in the MAPK/ERK signaling pathway, which is often activated in cancers with RAS mutations. - **Hydroxychloroquine** is an antimalarial and immunomodulatory agent that inhibits autophagy by blocking the fusion of autophagosomes with lysosomes. The rationale for this combination arises from preclinical and early clinical evidence suggesting that RAS-mutated tumors can escape MEK inhibition through upregulation of autophagy. Hydroxychloroquine suppresses this compensatory survival mechanism, while bevacizumab may enhance drug delivery to tumors and exert additional anti-tumor effects. This triplet regimen has been explored as a last-resort or experimental option in patients with refractory metastatic cancers harboring RAS mutations, particularly colorectal cancer[1][4][9].

Other names

bevacizumab + binimetinib + hydroxychloroquine